J&J wins CHMP nod for diabetes combo, but lags in competition
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Janssen-Cilag's Vokanamet, a combination of canagliflozin and metformin, for marketing approval in the EU. But Janssen, a few steps behind AstraZeneca in Europe and still suffering from the FDA's rejection last year, is now trailing in the tight diabetes combination competition.